COVID-19 Pneumonia in two Patients with Ankylosing Spondylitis Using Anti-TNF Agents
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
The new type of coronavirus (SARS-CoV2) reported to have originated in China in December 2019 has spread rapidly all over the world and has become a global problem. COVID-19 is more common and more severe in people with such comorbidities as cardiovascular disease, hypertension and diabetes. There is a lack of consensus on whether rheumato- logical diseases and drugs used in their treatment increase the risk of developing COVID-19. There is also lack of data in literature regarding the develop- ment of COVID-19, especially in patients with Anky- losing Spondylitis. This case presentation relates to two patients with Ankylosing Spondylitis using anti- TNF agents who were affected by COVID-19. The younger of the two, who had no comorbidities, healed quickly with antiviral and supportive therapy, while the older patient, who had cardiovascular and chronic kidney comorbidities, experienced an aggres- sive disease course and did not survive. The course of COVID-19 infection and mortality is strongly con- nected with underlying comorbidities. Our focus here is on rheumatological diseases, their immunosup- pressive treatments and their impact on the course of the novel type Coronavirus infection, based on two cases of Ankylosing Spondylitis, in light of literature.
Açıklama
Anahtar Kelimeler
Kaynak
Respiratory Case Reports
WoS Q Değeri
Scopus Q Değeri
Cilt
10
Sayı
2
